Search Results - "Legendre, C.M."

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome by Legendre, C.M, Licht, C, Muus, P, Greenbaum, L.A, Babu, S, Bedrosian, C, Bingham, C, Cohen, D.J, Delmas, Y, Douglas, K, Eitner, F, Feldkamp, T, Fouque, D, Furman, R.R, Gaber, O, Herthelius, M, Hourmant, M, Karpman, D, Lebranchu, Y, Mariat, C, Menne, J, Moulin, B, Nürnberger, J, Ogawa, M, Remuzzi, G, Richard, T, Sberro-Soussan, R, Severino, B, Sheerin, N.S, Trivelli, A, Zimmerhackl, L.B, Goodship, T, Loirat, C

“…This article describes the use of eculizumab in patients with atypical hemolytic–uremic syndrome. This C5 inhibitor was associated with improvement in…”
Get full text

Global Transplantation COVID Report March 2020 by Ahn, C., Amer, H., Anglicheau, D., Ascher, N.L., Baan, C.C., Battsetset, G., Bat-Ireedui, B., Berney, T., Betjes, M.G.H., Bichu, S., Birn, H., Brennan, D., Bromberg, J., Caillard, S., Cannon, R.M., Cantarovich, M., Chan, A., Chen, Z.S., Chapman, J.R., Cole, E.H., Cross, N., Durand, F., Egawa, H., Emond, J.C., Farrero, M., Friend, P.J., Geissler, E.K., Ha, J., Haberal, M.A., Henderson, M.L., Hesselink, D.A., Humar, A., Jassem, W., Jeong, J.C., Kaplan, B., Kee, T., Kim, S.J., Kumar, D., Legendre, C.M., Man, K., Moulin, B., Muller, E., Munkhbat, R., Od-Erdene, L., Perrin, P., Rela, M., Tanabe, K., Tedesco Silva, H., Tinckam, K.T., Tullius, S.G., Wong, G.

Get full text